Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBristol-Myers Squibb Company

Bristol-Myers Squibb Company

Healthcare Drug Manufacturers - General
PortfolioPortfolio WatchlistWatchlist
Company price
62.33 USD 0.19 ( 0.31%)
Last update at 2026-11-09T17:54:00Z
VOLUME
2608170
Market Cap
130182.20M
P/E
14.04

Momentum Score

…

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
61.80
Low
63.06
High
52 Week Price Range
41.13
Low
68.64
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
62.14
Dividend Yield
3.92%
Revenue TTM
49186.00M
Revenue Per Share
24.14
Gross Profit TTM
35247.00M
Debt / Equity
2.55
ROE
46.60%
Net Debt
36930.00M
ROCE
16.04%
Diluted EPS TTM
4.54

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 9328.00M -8379.00M 8440.00M 7713.00M 8098.00M
Minority interest -2.00M -15.00M -18.00M -18.00M -20.00M
Net income 7053.00M -8948.00M 8025.00M 6327.00M 6994.00M
Selling general administrative 5660.00M 6365.00M 6278.00M 7808.00M 7688.00M
Selling and marketing expenses 1584.00M 1500.00M 1400.00M 7814.00M 7690.00M
Gross profit 32602.00M 27432.00M 25357.00M 36022.00M 36445.00M
Reconciled depreciation 4011.00M 9600.00M 9817.00M 9595.00M 10023.00M
Ebit 10685.00M -6432.00M 9606.00M 10328.00M 10159.00M
Ebitda 14545.00M 3168.00M 19366.00M 19923.00M 20182.00M
Depreciation and amortization 3860.00M 9600.00M 9760.00M 9595.00M 10023.00M
Non operating income net other - - - -576.00M 720.00M
Operating income 12696.00M 9658.00M 8472.00M 10328.00M 10159.00M
Other operating expenses 35498.00M 38642.00M 36534.00M 37055.00M 37848.00M
Interest expense 1510.00M 1947.00M 1166.00M 1232.00M 1334.00M
Tax provision 2272.00M 554.00M 322.00M 1368.00M 1084.00M
Interest income 1025.00M 1453.00M 877.00M 1862.00M 550.00M
Net interest income -1891.00M -1947.00M -1144.00M -1232.00M -1334.00M
Income tax expense 2272.00M 554.00M 400.00M 1368.00M 1084.00M
Total revenue 48194.00M 48300.00M 45006.00M 46159.00M 46385.00M
Total operating expenses 19906.00M 17774.00M 16885.00M 26918.00M 27908.00M
Cost of revenue 15592.00M 20868.00M 19649.00M 10137.00M 9940.00M
Total other income expense net -3368.00M -18037.00M -32.00M -2615.00M -2061.00M
Net income from continuing ops 7055.00M -8933.00M 8303.00M 6345.00M 7014.00M
Net income applicable to common shares 7054.00M -8948.00M 8025.00M 6327.00M 6994.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 90038.00M 92603.00M 95159.00M 96820.00M 109314.00M
Intangible assets 19103.00M 23643.00M 27485.00M 36355.00M 42775.00M
Other current assets 1502.00M 1940.00M 1564.00M 1596.00M 1290.00M
Total liab 71532.00M 76215.00M 65674.00M 65702.00M 73308.00M
Total stockholder equity 18473.00M 16335.00M 29430.00M 31061.00M 35946.00M
Deferred long term liab - - - 2166.00M 4501.00M
Other current liab 16400.00M 16431.00M 14351.00M 13106.00M 10109.00M
Common stock 292.00M 292.00M 292.00M 292.00M 292.00M
Capital stock 292.00M 292.00M 292.00M 292.00M 292.00M
Retained earnings 16896.00M 14912.00M 28766.00M 25503.00M 23820.00M
Other liab - - - 7392.00M 10961.00M
Good will 21754.00M 21719.00M 21169.00M 21149.00M 20502.00M
Other assets 8174.00M 7381.00M 5049.00M 2877.00M 3342.00M
Cash 10209.00M 10346.00M 11464.00M 9123.00M 13979.00M
Cash and equivalents 10209.00M 10346.00M 11464.00M 9123.00M 13979.00M
Total current liabilities 23417.00M 23774.00M 22262.00M 21890.00M 21868.00M
Current deferred revenue - - 271.00M 1344.00M 3693.00M
Net debt 36930.00M 40854.00M 30000.00M 31594.00M 31617.00M
Short term debt 2463.00M 2227.00M 3281.00M 4400.00M 5117.00M
Short long term debt 2261.00M 2046.00M 3119.00M 4264.00M 4948.00M
Short long term debt total 47139.00M 51200.00M 41464.00M 40717.00M 45596.00M
Other stockholder equity 2808.00M 2369.00M 1918.00M 6547.00M 13102.00M
Property plant equipment 9125.00M 8360.00M 8036.00M 6255.00M 6049.00M
Total current assets 29390.00M 29780.00M 31770.00M 27273.00M 33262.00M
Long term investments 2507.00M 2508.00M 2063.00M 2187.00M 2713.00M
Net tangible assets - - - -25947.00M -28236.00M
Short term investments 464.00M 513.00M 816.00M 130.00M 3242.00M
Net receivables 14525.00M 14424.00M 15264.00M 13937.00M 12516.00M
Long term debt 42850.00M 47603.00M 36653.00M 35056.00M 39605.00M
Inventory 2690.00M 2557.00M 2662.00M 2339.00M 2095.00M
Accounts payable 3575.00M 3602.00M 3259.00M 3040.00M 2949.00M
Noncontrolling interest in consolidated entity - - 55.00M 57.00M 60.00M
Accumulated other comprehensive income -1523.00M -1238.00M -1546.00M -1281.00M -1268.00M
Additional paid in capital - - 0.00M - -
Common stock total equity - - - 292.00M 292.00M
Retained earnings total equity - - - 25503.00M 23820.00M
Treasury stock - - -43766.00M - -31259.00M
Non currrent assets other 2781.00M 2357.00M 1432.00M 1037.00M 1655.00M
Non current assets total 60648.00M 62823.00M 63389.00M 69547.00M 76052.00M
Capital lease obligations 2028.00M 1551.00M 1692.00M 1397.00M 1043.00M
Long term debt total 42850.00M 47603.00M 36653.00M 35056.00M 39605.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 52.00M -21352.00M 264.00M 3037.00M 1297.00M
Change to liabilities - - - -887.00M 45.00M
Total cashflows from investing activities -4132.00M -21352.00M -2295.00M -1062.00M -538.00M
Net borrowings -5175.00M 10096.00M 456.00M -5311.00M -6182.00M
Total cash from financing activities -10348.00M 5127.00M -9416.00M -16962.00M -16224.00M
Change to operating activities - - - -183.00M 606.00M
Net income 7055.00M -8933.00M 8040.00M 6345.00M 7014.00M
Change in cash -137.00M -1172.00M 2194.00M -4991.00M -657.00M
Begin period cash flow 10347.00M 11519.00M 9325.00M 14316.00M 14973.00M
End period cash flow 10218.00M 10347.00M 11519.00M 9325.00M 14316.00M
Total cash from operating activities 14156.00M 15190.00M 13860.00M 13066.00M 16207.00M
Depreciation 4011.00M 9600.00M 9760.00M 10276.00M 10686.00M
Other cashflows from investing activities -2821.00M 1099.00M -1086.00M -2981.00M -862.00M
Dividends paid 5045.00M 4863.00M 4744.00M 4634.00M 4396.00M
Change to inventory -184.00M -486.00M -751.00M -69.00M 13.00M
Change to account receivables -295.00M 264.00M -995.00M -663.00M -2117.00M
Sale purchase of stock 0.00M 0.00M -5155.00M -8001.00M -6287.00M
Other cashflows from financing activities -128.00M -106.00M 27.00M 7104.00M 641.00M
Change to netincome - - - -1078.00M -748.00M
Capital expenditures 1311.00M 1248.00M 1209.00M 1118.00M 973.00M
Change receivables - - - -663.00M -1054.00M
Cash flows other operating - - - -858.00M 251.00M
Cash and cash equivalents changes - - - -4958.00M -555.00M
Change in working capital -455.00M 810.00M -1914.00M -2229.00M -1253.00M
Stock based compensation 553.00M 507.00M 518.00M 457.00M 583.00M
Other non cash items 3957.00M 15295.00M 744.00M 955.00M 570.00M
Free cash flow 12845.00M 13942.00M 12651.00M 11948.00M 15234.00M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - General

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BMY
Bristol-Myers Squibb Company		 0.19
0.31%		 62.33 14.04 9.81 2.65 5.87 3.35 9.81
LLY
Eli Lilly and Company		 50.73
3.75%		 1404.73 38.16 24.15 12.72 29.95 13.31 25.43
JNJ
Johnson & Johnson		 6.09
2.20%		 282.31 30.96 20.79 6.58 7.55 6.84 19.73
ABBV
AbbVie Inc		 1.97
0.67%		 293.27 74.10 16.21 7.22 50.46 8.18 27.04
RHHVF
Roche Holding AG Participation		 17.28
3.66%		 490.05 24.16 16.53 5.71 8.88 4.94 14.76

Profile*

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Route 206 & Province Line Road, Princeton, NJ, United States, 08543

609 252 4621

https://www.bms.com

32500

Name Title Year Born
Dr. Giovanni Caforio M.D. Chairman & CEO 1965
Mr. David V. Elkins Exec. VP & CFO 1968
Ms. Sandra Leung Esq. Exec. VP & Gen. Counsel 1961
Dr. Christopher S. Boerner Exec. VP & Chief Commercialization Officer 1971
Mr. Rupert Vessey BCH, BM, DPHIL, M.A. Exec. VP and Pres of Research & Early Devel. 1965
Mr. Greg Meyers Exec. VP and Chief Digital & Technology Officer 1973
Mr. Timothy Power VP & Head of Investor Relations NA
Ms. Cari Gallman Sr. VP & Chief Compliance and Ethics Officer NA
Ms. Ann M. Powell Judge Exec. VP & Chief HR Officer 1966
Mr. Jitendra Tyagi Head of US Drug Makers - India NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.88%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.16%

  • Financial Services

    +1.33%

  • Healthcare

    +1.50%

  • Industrials

    +2.97%

  • Real Estate

    +0.41%

  • Technology

    +1.27%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…